



Docket No. : 2245.005A

17w

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicant(s): Berdini et al

Serial No. : 10/563,350

Filed: January 3, 2006

Title: Pharmaceutical Compounds

Confirmation No. : 8772

Group Art Unit: Unassigned

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is being:

- ☐ submitted together with the application being filed herein; or
- ☒ submitted for the first time; or
- ☐ submitted as a Supplemental Information Disclosure Statement in addition to an Information Disclosure Statement, which was
- ☐ filed on _____; or
- ☐ filed together with the application on _____, and such submission is being made:
- ☒ under 37 CFR 1.97(b), within three months of filing national application or date of entry of international application, or before mailing date of first office action on the merits, whichever occurs last; or
- ☐ under 37 CFR 1.97(c) together with either a:
- ☐ Statement under 37 CFR 1.97(e); or
- ☐ \$180.00 fee under 37 CFR 1.17(p), after the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first; or
- ☐ under 37 CFR 1.97(d), filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee, together with a:
- ☐ Statement under 37 CFR 1.97(e); and
- ☐ \$180.00 fee under 37 CFR 1.17(p);
- ☒ and, furthermore, please note that this Information Disclosure Statement is being submitted:
- ☒ to disclose references cited in the Search Report in a related foreign application; and
- ☐ within 30 days of receipt of the Search Report (see 37 CFR 1.704(d)).

☐ Comment(s):

Applicant(s) submit herewith an Information Disclosure Citation form listing patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application, and for which there may be a duty to disclose in accordance with 37 CFR 1.56, together with any required copies of the listed references.

It is requested that the information disclosed herein be made of record in this application.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date of Deposit: June 28, 2006


Erika J. Senska, Esq.

Respectfully submitted,

Erika J. Senska, Esq.

Erika J. Senska, Esq.
Attorney for Applicant(s)
Registration No. 53,312
Dated: June 28, 2006

HESLIN ROTHENBERG FARLEY & MESITI P.C.
5 Columbia Circle
Albany, New York 12203
Telephone: (518) 452-5600
Facsimile: (518) 452-5579

INFORMATION DISCLOSURE CITATION 	Docket No 2245.005A	Serial No.: 10/563,350
	Applicant(s): Berdini et al.	Examiner: Unassigned
	Filing Date: January 3, 2006	GAU: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial	Ref	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial	Ref	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	CA	WO 03/035065	October 24, 2002	PCT				
	CB	WO 03/004488	July 2, 2002	PCT				

OTHER DOCUMENTS

(Including Author, title, Date, Pertinent Pages, etc.)		
DA	Essassi, E.M., et al., "Synthese Et Hererocyclisation Des (Pyrazolyl-3(5))-2 Benzimidazoles En Catalyse Par Transfert De Phase", Bull. Soc. Chim. Belg., Vol. 96, pp. 63-67 (1987).	
EXAMINER:	Date Considered	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		